Print This Page

This page lists current opportunities from CIP.

For information about the funding process, go to Mechanisms or Guidelines.

The NCI's Division of Extramural Activities provides information about newly approved concepts, which may become RFAs and PAs. Check the Concepts Cleared at the NCI Board of Scientific Advisors Meeting web site for the earliest possible information about future initiatives.

• PAR-13-185: Image-guided Drug Delivery in Cancer (R01)

  • Release Date: May 14, 2013
  • Application Receipt Date: June 19, 2013; November 19, 2013; June 19, 2014; November 19, 2014; June 19, 2015; November 19, 2015
  • Expiration Date: November 20, 2015
  • Contacts:

    Contact: Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 240-276-5921

    Please see the FOA for a complete list of contacts.

  This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

• PAR-13-169: Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)

  • Release Date: May 14, 2013
  • Application Receipt Date: Standard dates apply: see http://grants.nih.gov/grants/funding/submissionschedule.htm
  • Expiration Date: May 8, 2016
  • Contacts:

    Houston Baker, Ph.D.; Phone: 240-276-5908; Email: bakerhou@mail.nih.gov

    Please see the FOA for a complete list of contacts.

  This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either preclinical or clinical in vivo imaging systems and/or methods that are designed to solve a targeted cancer problem. The proposed imaging system/methods may include single or multi-modality in vivo imaging and spectroscopy systems, image-guided and drug delivery systems, image analysis, and related research resources. This FOA may also include, as a secondary goal, support for other laboratory imaging or reference methods as required to validate the performance of the proposed in vivo imaging system and/or methods. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following examples, among others: (a) current commercially supported imaging systems/methods, (b) next-generation imaging systems/methods, (c) quality assurance and quality control methods, (d) validation and correlation studies, (e) quantitative imaging methods, and (f) related research resources. Because appropriate applications must be translational in scope, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. The partnerships on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their proposed imaging system/methods to solve a targeted cancer problem. This FOA will support clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. This FOA will not support commercial production, or basic research projects that do not emphasize translational development and optimization of the methods for a targeted cancer problem.

• PAR-11-216: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)

  • Release Date: May 24, 2011
  • Application Receipt Date: See below
  • Expiration Date: March 14, 2014
  • Contacts:

    Imaging trials:

    Lalitha K. Shankar, M.D., Ph.D., NCI, Phone: 240-276-6510, (shankarl@mail.nih.gov)
    Frank I. Lin, M.D., NCI, Phone: 240-276-5932, (frank.lin2@nih.gov)

    Image-Guided Intervention trials:

    Keyvan Farahani, Ph.D., NCI, Phone: 240-276-5921, (farahank@mail.nih.gov)

    Radiation Therapy trials:

    Bhadrasain Vikram, M.D., NCI, Phone: 240-276-5690, (vikramb@mail.nih.gov)

  • Application Receipt/Submission Date(s): July 27, 2011; November 10, 2011; March 13, 2012; July 11, 2012; November 13, 2012; March 13, 2013; July 11, 2013; November 13, 2013; March 13, 2014, by 5:00 PM local time of applicant organization.

  This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Center and/or Cooperative Groups.

  See full description in NIH Guide: PAR-11-216;

• PAR-11-150: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)

  • Release Date: March 14, 2011
  • Application Receipt Date: Standard dates
  • Expiration Date: May 8, 2014
  • Contacts:

    Robert J. Nordstrom, Ph.D. (nordstrr@mail.nih.gov) at 240-276-5934

  The Cancer Imaging Program, (NCI), solicits applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned Phase 1-2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.

  See the CIP QIN website for a description of the program.

  • No set-aside

  See full description in NIH Guide: PAR-11-150

  Clarification of Scope and Requirements of PAR-11-150: NOT-CA-11-011

• 1